BioCentury | Aug 21, 2020
Deals

Aug. 20 Quick Takes: Funding for Alzheon’s Alzheimer’s Phase III; plus Merck, FDA guidance, LumiraDx, RACE for Children, blood plasma and Novo-Evotec

...$47 million to Alzheon Inc. over five years to conduct a Phase III study of ALZ-801...
...had twice sought to raise money for the trial via IPOs that were later withdrawn. ALZ-801...
...more than €150 million in milestones per product.TARGETSAPOE4 – Apolipoprotein E epsilon 4 Paul Bonanos ALZ-801, blu8499, NRM8499, NRM-8499 Keytruda...
BioCentury | Dec 6, 2019
Clinical News

Biogen Alzheimer’s data won’t sway believers or doubters either way

...the agents that have shown an effect on cognition in early trials, such as Alzheon’s ALZ-801...
...AD Subgroup ” and “ ALZ-801 Data Justify Pursuit in Homozygous APOE Carriers ”) . ALZ-801...
BioCentury | Jan 18, 2019
Financial News

Alzheon pulls second IPO attempt

...IPO seeking $41.2 million. In its August S-1, Alzheon revised its plans for lead compound ALZ-801...
...time for publication regarding whether it has alternative funding plans for its Phase IIb trial. ALZ-801...
...ALZ-801 is based on the β amyloid hypothesis. Alzheon Inc., Framingham, Mass. Chris Lieu ALZ-801, blu8499, NRM8499, NRM-8499 Alzheon...
BioCentury | Aug 31, 2018
Financial News

Alzheon proposes new IPO seeking $41.2M

...This year, Alzheon plans to start a Phase Ib trial to evaluate the pharmacokinetics of ALZ-801...
...IIb trial next half of candidate to treat APOE4-homozygous patients with early to mild AD. ALZ-801...
...May 1 (see “Alzheon Proposes IPO” ). Alzheon Inc, Framingham, Mass. Jaime De Leon ALZ-801, blu8499, NRM8499, NRM-8499 Alzheon...
BioCentury | May 4, 2018
Financial News

Alzheimer's company Alzheon postpones IPO

...filing, Alzheon said it intended to start Phase III testing this year of lead candidate ALZ-801...
...disease. In April 30's statement, it said it is evaluating alternatives to funding the program. ALZ-801...
...Alzheon has raised $27.8 million in equity funding. Alzheon Inc., Framingham, Mass. Allison Johnson ALZ-801, blu8499, NRM8499, NRM-8499 Alzheon...
BioCentury | Apr 30, 2018
Financial News

Alzheon postpones NASDAQ IPO

...filing, Alzheon said it intended to start Phase III testing this year of lead candidate ALZ-801...
...Alzheimer's disease. In Monday's statement, it said it is evaluating alternatives to funding the program. ALZ-801...
...Nov. 25, 2013) . Alzheon has raised $27.8 million in equity funding. Allison Johnson ALZ-801, blu8499, NRM8499, NRM-8499 Alzheon...
BioCentury | Mar 23, 2018
Financial News

Alzheon proposes IPO

...JMP Securities. Alzheon plans to start a Phase III trial this year of lead candidate ALZ-801...
...an oral small molecule prodrug of tramiprosate, to treat Alzheimer's disease. Alzheon obtained rights to ALZ-801...
...total AD population. Alzheon has raised $27.8 million in equity funding. Alzheon Inc., Framingham, Mass. Paul Bonanos ALZ-801 Alzhemed tramiprosate Alzheon...
BioCentury | Mar 19, 2018
Financial News

Alzheimer's play Alzheon files for IPO

...candidate ALZ-801, its oral small molecule prodrug of tramiprosate, to treat Alzheimer's disease. Alzheon obtained ALZ-801's...
...for 10-15% of the total AD population. Alzheon has raised $27.8 million in equity funding. Paul Bonanos ALZ-801 tramiprosate Alzheon...
BioCentury | Oct 27, 2017
Clinical News

Alzheon reports Phase I bridging dose analysis data for AD candidate ALZ-801

...evaluating the safety and pharmacokinetics of various dosing regimens and formulations of Alzheimer’s disease candidate ALZ-801...
...Nov. 16, 2015 ). ALZ-801 was well tolerated with no serious adverse events reported. Additionally, ALZ-801...
...AD. Alzheon Inc. , Framingham, Mass. Bellus Health Inc. (TSX:BLU), Laval, Quebec Product: ALZ-801 (formerly BLU8499...
BioCentury | Apr 26, 2017
Clinical News

Alzheon identifies MOA for AD candidate

...identified the mechanism of action for tramiprosate, the active agent in its Alzheimer's disease candidate ALZ-801...
...and protein misfolding, enveloping and stabilizing the monomers. Tramiprosate also prevents growth of existing oligomers. ALZ-801...
...an inhibitor of amyloid formation and neurotoxicity. Alzheon plans to begin a pivotal study of ALZ-801...
Items per page:
1 - 10 of 24